Primary Biliary Cholangitis Clinical Trials

Find Primary Biliary Cholangitis Clinical Trials Near You

A Double-blind, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium on Normalization of Alkaline Phosphatase Levels in Patients With Primary Biliary Cholangitis and an Incomplete Response or Intolerance to Ursodeoxycholic Acid

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Study of Saroglitazar Magnesium for PBC Patients with Incomplete Response or Intolerant to UDCA Therapy

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Adults between 18 and 80 years of age (both inclusive at screening)

• History of confirmed Primary Biliary Cholangitis diagnosis

• Ursodeoxycholic acid treatment for at least 12 months and a stable dose for at least 6 months prior to first screening visit OR intolerant to Ursodeoxycholic acid (last dose of Ursodeoxycholic acid at least 3 months prior to first screening visit).

• Average Alkaline Phosphatase at both screening Visits 1 and 2: \> 1× Upper Limit of Normal and \< 1.67× Upper Limit of Normal, and \< 30% variance between both levels

• Total bilirubin ≤ 2 x Upper Limit of Normal at screening (Visit 1), unless there is a prior diagnosis of Gilbert's syndrome. For participants with Gilbert's syndrome, direct bilirubin is to be ≤ 2 x Upper Limit of Normal at screening (Visit 1).

• Must have given written informed consent (signed and dated).

Locations
United States
Florida
US203
RECRUITING
Lakewood Rch
Contact Information
Primary
Farheen Shaikh
fshaikh@zydustherapeutics.com
609-730-1900
Backup
Deven Parmar
dparmar@zydustherapeutics.com
609-703-1900
Time Frame
Start Date: 2026-08-11
Estimated Completion Date: 2028-11
Participants
Target number of participants: 90
Treatments
Experimental: Saroglitazar Magnesium 1 mg
Saroglitazar magnesium 1 mg, once daily, orally each morning before breakfast
Placebo_comparator: Placebo
Matching Placebo once daily, orally each morning before breakfast
Sponsors
Leads: Zydus Therapeutics Inc.

This content was sourced from clinicaltrials.gov